# Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

> **NCT00985153** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3927 (actual)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
- **BIOLOGICAL:** Comparator: Varivax
- **BIOLOGICAL:** Comparator: M-M-R II

## Key facts

- **NCT ID:** NCT00985153
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2001-05
- **Final completion:** 2001-05
- **Target enrollment:** 3927 (ACTUAL)
- **Last updated:** 2015-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985153, "Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00985153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*